Juno Therapeutics, Inc. v. Kite Pharma, Inc.
1:16-cv-01243
Overview
Parties
Defendant
Kite Pharma, Inc. Operating Company
Represented By
7 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Plaintiff
Sloan Kettering Institute for Cancer Research Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Memorial Sloan Kettering Cancer Center Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Juno Therapeutics, Inc. Operating Company
Represented By
5 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 7,446,190 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 38,387,202 P | US Continuation / Sibling | View Official Patent → |
Kite Pharma, Inc. v. Sloan Kettering Institute for Cancer Research et al.
Juno Therapeutics, Inc. v. Kite Pharma, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7446190
Nucleic acids encoding chimeric T cell receptors
|
Filed: 2003-05-28
Issued: 2008-11-04
|
Expired (Term Ended)
+458d PTA
Expires: 2024-08-28
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+458 days) / Cellect Scrutiny — Over 458 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
13
Dispositive
11
Granted
1
Denied
0
Pending / Review
10
Motions by Category
Key Dispositive Motions & Rulings